Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (381-390 of 466) with videos related to

Pageof 47
Sort By:
Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Pageof 47

Showing results (381-390 of 466) with videos related to

Sort By:
Pageof 47
Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Leukemia & Lymphoma|October 16, 2023
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphomaGeorg Hess, Martin Dreyling, Lucie Oberic, et al.
Pageof 47